Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805265384> ?p ?o ?g. }
- W2805265384 endingPage "2224" @default.
- W2805265384 startingPage "2213" @default.
- W2805265384 abstract "Background Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. Methods We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA. Eligible participants were aged 18 years or older with active psoriatic arthritis and plaque psoriasis affecting at least 3% of their body surface area, with three or more of 66 tender joints and three or more of 68 swollen joints, who had an inadequate response or intolerance to standard treatments. We randomly assigned patients (2:1) via a central interactive web-response system using computer-generated permuted blocks with a block size of six, stratified by previous anti-tumour necrosis factor-α use, to receive subcutaneous guselkumab 100 mg or placebo at week 0, week 4, and every 8 weeks thereafter for 24 weeks. Patients, investigators, and site staff were masked to treatment assignment until final database lock at week 56. At week 16, patients with less than 5% improvement in swollen and tender joint counts were eligible for early escape to ustekinumab. At week 24, the remaining placebo-treated patients crossed over to receive guselkumab 100 mg at weeks 24, 28, 36, and 44 and guselkumab-treated patients received a placebo injection at week 24, followed by guselkumab injections at weeks 28, 36, and 44. The primary endpoint was the proportion of patients with at least 20% improvement at week 24 in signs and symptoms of psoriatic arthritis according to American College of Rheumatology criteria (ACR20) in the modified intention-to-treat population (ie, all randomly assigned patients who received at least one dose of study treatment). Safety analyses included patients according to the study drug received. This study is registered with ClinicalTrials.gov, number NCT02319759. Findings Between March 27, 2015, and Jan 17, 2017, we randomly assigned 149 patients to treatment: 100 to guselkumab and 49 to placebo. 17 (35%) of 49 patients in the placebo group and ten (10%) of 100 patients in the guselkumab group were eligible for early escape to ustekinumab at week 16. 29 (59%) of 49 patients in the placebo group crossed over and received guselkumab at week 24. Three (6%) of 49 patients in the placebo group, one (3%) of 29 patients who crossed over from placebo to guselkumab, and six (6%) of 100 patients in the guselkumab group discontinued study treatment before week 44. 58 (58%) of 100 patients in the guselkumab group and nine (18%) of 49 patients in the placebo group achieved an ACR20 response at week 24 (percentage difference 39·7% [95% CI 25·3–54·1]; p<0·0001). Between week 0 and week 24, 36 (36%) of 100 guselkumab-treated patients and 16 (33%) of 49 placebo-treated patients had at least one adverse event. The most frequent adverse event was infection in both groups (16 [16%] of 100 patients in the guselkumab group vs ten [20%] of 49 patients in the placebo group). The prevalence of adverse events between week 0 and week 56 in guselkumab-treated patients (51 [40%] of 129) indicated no disproportional increase with longer guselkumab exposure. No deaths occurred. Interpretation Guselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and was well tolerated during 44 weeks of treatment. The results of this study support further development of guselkumab as a novel and comprehensive treatment in psoriatic arthritis. Funding Janssen Research & Development. Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA. Eligible participants were aged 18 years or older with active psoriatic arthritis and plaque psoriasis affecting at least 3% of their body surface area, with three or more of 66 tender joints and three or more of 68 swollen joints, who had an inadequate response or intolerance to standard treatments. We randomly assigned patients (2:1) via a central interactive web-response system using computer-generated permuted blocks with a block size of six, stratified by previous anti-tumour necrosis factor-α use, to receive subcutaneous guselkumab 100 mg or placebo at week 0, week 4, and every 8 weeks thereafter for 24 weeks. Patients, investigators, and site staff were masked to treatment assignment until final database lock at week 56. At week 16, patients with less than 5% improvement in swollen and tender joint counts were eligible for early escape to ustekinumab. At week 24, the remaining placebo-treated patients crossed over to receive guselkumab 100 mg at weeks 24, 28, 36, and 44 and guselkumab-treated patients received a placebo injection at week 24, followed by guselkumab injections at weeks 28, 36, and 44. The primary endpoint was the proportion of patients with at least 20% improvement at week 24 in signs and symptoms of psoriatic arthritis according to American College of Rheumatology criteria (ACR20) in the modified intention-to-treat population (ie, all randomly assigned patients who received at least one dose of study treatment). Safety analyses included patients according to the study drug received. This study is registered with ClinicalTrials.gov, number NCT02319759. Between March 27, 2015, and Jan 17, 2017, we randomly assigned 149 patients to treatment: 100 to guselkumab and 49 to placebo. 17 (35%) of 49 patients in the placebo group and ten (10%) of 100 patients in the guselkumab group were eligible for early escape to ustekinumab at week 16. 29 (59%) of 49 patients in the placebo group crossed over and received guselkumab at week 24. Three (6%) of 49 patients in the placebo group, one (3%) of 29 patients who crossed over from placebo to guselkumab, and six (6%) of 100 patients in the guselkumab group discontinued study treatment before week 44. 58 (58%) of 100 patients in the guselkumab group and nine (18%) of 49 patients in the placebo group achieved an ACR20 response at week 24 (percentage difference 39·7% [95% CI 25·3–54·1]; p<0·0001). Between week 0 and week 24, 36 (36%) of 100 guselkumab-treated patients and 16 (33%) of 49 placebo-treated patients had at least one adverse event. The most frequent adverse event was infection in both groups (16 [16%] of 100 patients in the guselkumab group vs ten [20%] of 49 patients in the placebo group). The prevalence of adverse events between week 0 and week 56 in guselkumab-treated patients (51 [40%] of 129) indicated no disproportional increase with longer guselkumab exposure. No deaths occurred. Guselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and was well tolerated during 44 weeks of treatment. The results of this study support further development of guselkumab as a novel and comprehensive treatment in psoriatic arthritis." @default.
- W2805265384 created "2018-06-13" @default.
- W2805265384 creator A5002094024 @default.
- W2805265384 creator A5004714398 @default.
- W2805265384 creator A5005291921 @default.
- W2805265384 creator A5006526834 @default.
- W2805265384 creator A5007351753 @default.
- W2805265384 creator A5008067100 @default.
- W2805265384 creator A5008286260 @default.
- W2805265384 creator A5008473117 @default.
- W2805265384 creator A5009241834 @default.
- W2805265384 creator A5009710595 @default.
- W2805265384 creator A5014727260 @default.
- W2805265384 creator A5015084747 @default.
- W2805265384 creator A5015186627 @default.
- W2805265384 creator A5015686773 @default.
- W2805265384 creator A5021376488 @default.
- W2805265384 creator A5023552165 @default.
- W2805265384 creator A5027994534 @default.
- W2805265384 creator A5030325032 @default.
- W2805265384 creator A5033754966 @default.
- W2805265384 creator A5035577773 @default.
- W2805265384 creator A5035683291 @default.
- W2805265384 creator A5036081522 @default.
- W2805265384 creator A5037777681 @default.
- W2805265384 creator A5038881151 @default.
- W2805265384 creator A5041653844 @default.
- W2805265384 creator A5044877399 @default.
- W2805265384 creator A5046003718 @default.
- W2805265384 creator A5047128433 @default.
- W2805265384 creator A5047155990 @default.
- W2805265384 creator A5049859852 @default.
- W2805265384 creator A5054608926 @default.
- W2805265384 creator A5056716675 @default.
- W2805265384 creator A5060724182 @default.
- W2805265384 creator A5061843197 @default.
- W2805265384 creator A5063737244 @default.
- W2805265384 creator A5067814311 @default.
- W2805265384 creator A5071926023 @default.
- W2805265384 creator A5072865266 @default.
- W2805265384 creator A5075502252 @default.
- W2805265384 creator A5076757637 @default.
- W2805265384 creator A5077437275 @default.
- W2805265384 creator A5080374673 @default.
- W2805265384 creator A5080655694 @default.
- W2805265384 creator A5083084803 @default.
- W2805265384 creator A5084326617 @default.
- W2805265384 creator A5084697265 @default.
- W2805265384 date "2018-06-01" @default.
- W2805265384 modified "2023-10-17" @default.
- W2805265384 title "Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study" @default.
- W2805265384 cites W1836263069 @default.
- W2805265384 cites W1935617463 @default.
- W2805265384 cites W1983418868 @default.
- W2805265384 cites W2041959340 @default.
- W2805265384 cites W2045317929 @default.
- W2805265384 cites W2048020246 @default.
- W2805265384 cites W2083180635 @default.
- W2805265384 cites W2094124191 @default.
- W2805265384 cites W2103524303 @default.
- W2805265384 cites W2108984264 @default.
- W2805265384 cites W2116828514 @default.
- W2805265384 cites W2137101132 @default.
- W2805265384 cites W2512436288 @default.
- W2805265384 cites W2548333195 @default.
- W2805265384 cites W2558568353 @default.
- W2805265384 cites W2570140560 @default.
- W2805265384 cites W2570141807 @default.
- W2805265384 cites W2602791888 @default.
- W2805265384 cites W2606035821 @default.
- W2805265384 cites W2620369605 @default.
- W2805265384 cites W2759528599 @default.
- W2805265384 cites W823422456 @default.
- W2805265384 doi "https://doi.org/10.1016/s0140-6736(18)30952-8" @default.
- W2805265384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29893222" @default.
- W2805265384 hasPublicationYear "2018" @default.
- W2805265384 type Work @default.
- W2805265384 sameAs 2805265384 @default.
- W2805265384 citedByCount "135" @default.
- W2805265384 countsByYear W28052653842018 @default.
- W2805265384 countsByYear W28052653842019 @default.
- W2805265384 countsByYear W28052653842020 @default.
- W2805265384 countsByYear W28052653842021 @default.
- W2805265384 countsByYear W28052653842022 @default.
- W2805265384 countsByYear W28052653842023 @default.
- W2805265384 crossrefType "journal-article" @default.
- W2805265384 hasAuthorship W2805265384A5002094024 @default.
- W2805265384 hasAuthorship W2805265384A5004714398 @default.
- W2805265384 hasAuthorship W2805265384A5005291921 @default.
- W2805265384 hasAuthorship W2805265384A5006526834 @default.
- W2805265384 hasAuthorship W2805265384A5007351753 @default.
- W2805265384 hasAuthorship W2805265384A5008067100 @default.
- W2805265384 hasAuthorship W2805265384A5008286260 @default.
- W2805265384 hasAuthorship W2805265384A5008473117 @default.
- W2805265384 hasAuthorship W2805265384A5009241834 @default.
- W2805265384 hasAuthorship W2805265384A5009710595 @default.
- W2805265384 hasAuthorship W2805265384A5014727260 @default.
- W2805265384 hasAuthorship W2805265384A5015084747 @default.